Levity Pricing: Ozempic, Mounjaro & Wegovy Costs Compared 2026

Last reviewed: September 10, 2026 Last updated: September 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Levity offers FDA-approved branded GLP-1 medications—Ozempic, Mounjaro, and Wegovy—billed approximately every four weeks with no separate membership fee. A first-month welcome offer (WELCOME) reduces the initial charge by $50, bringing Ozempic to $1,149, Mounjaro to $1,249, and Wegovy to $1,549 for the first four-week supply (all figures captured September 4, 2026 at https://www.joinlevity.com/). Standard refill rates are $1,199, $1,299, and $1,599 per four weeks, respectively. Over 52 weeks (13 four-week billing cycles), Levity's Ozempic costs $15,537, Mounjaro $16,837, and Wegovy $20,737—effective monthly costs of $1,295, $1,403, and $1,728 (our calculation). Compounded semaglutide injection via PlexusDx runs $189/month month-to-month ($2,268 over 12 months), and compounded tirzepatide injection $289/month ($3,468 over 12 months). Patients choosing Levity gain the assurance of FDA-approved branded medications but pay five to nine times more than compounded alternatives carrying the same active pharmaceutical ingredients.

At-a-glance comparison

All Levity figures captured September 4, 2026 via intake completion at https://www.joinlevity.com/. PlexusDx pricing captured July 17–23, 2026 from live product pages. 52-week totals and effective monthly costs are our calculations.

Billing cadence and the four-week-versus-monthly distinction

Levity bills approximately every four weeks, meaning 13 billing cycles occur over a 52-week year rather than 12 calendar months. This creates a divergence between advertised per-cycle rates and true annual burden. Ozempic's $1,199 refill rate sounds slightly cheaper than Wegovy's $1,599, but over 52 weeks the difference compounds: $15,537 for Ozempic versus $20,737 for Wegovy—a $5,200 annual gap (our calculation).

To derive an effective monthly cost, we divide the 52-week total by 12 calendar months. For Levity Ozempic that yields $1,295 per month; for Mounjaro $1,403; for Wegovy $1,728. PlexusDx bills on a true 30-day calendar month, so the stated rate is the realized rate: $189 per month for semaglutide injection, $289 for tirzepatide injection, every month.

Levity's first-month welcome offer and refill economics

Levity advertises a $50 welcome offer via the WELCOME promotion, applied to the first four-week supply. This brings Ozempic's opening charge from $1,199 to $1,149, Mounjaro from $1,299 to $1,249, and Wegovy from $1,599 to $1,549 (all verified September 4, 2026). After the first cycle, every subsequent four-week shipment bills at the full standard rate with no further reduction.

Expressed as a percentage, the $50 WELCOME reduction represents 4.2% off Ozempic, 3.9% off Mounjaro, and 3.1% off Wegovy—a modest one-time savings that has negligible impact on the 52-week total. Over a full year the Ozempic patient pays $15,537 instead of $15,587 (a net $50 reduction), Mounjaro $16,837 instead of $16,887, and Wegovy $20,737 instead of $20,787.

Branded FDA-approved medications versus compounded formulations

Levity dispenses Ozempic, Mounjaro, and Wegovy in their FDA-approved, Novo Nordisk– or Eli Lilly–manufactured forms. These products underwent phase-three randomized controlled trials, hold New Drug Application approvals, and carry the brand manufacturer's quality controls. Patients choosing branded options accept the higher price in exchange for that regulatory and manufacturing provenance.

PlexusDx offers compounded semaglutide and tirzepatide prepared by licensed 503A compounding pharmacies. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies. The active pharmaceutical ingredient is identical—semaglutide in Ozempic and Wegovy, tirzepatide in Mounjaro—but the finished preparation, excipients, and device format may differ. Compounded formulations cost less because they bypass brand-manufacturer supply chains and do not carry the development-cost premium embedded in branded pricing.

A patient starting on Levity Ozempic will pay $15,537 over 52 weeks for branded semaglutide; the same patient switching to PlexusDx compounded semaglutide injection would pay $2,268 over 12 months—a savings of $13,269, or 85% (our calculation). For tirzepatide the gap is $13,369 annually (Levity Mounjaro $16,837 minus PlexusDx tirzepatide injection $3,468). Whether that difference justifies the regulatory distinction is a clinical and personal finance judgment; the arithmetic itself is unambiguous.

Inclusions: what is bundled in each monthly charge

Levity's per-cycle price includes medication, clinician consultation, ongoing care access, and shipping, with no separate membership fee (confirmed September 4, 2026). That all-inclusive model mirrors PlexusDx, which likewise bundles the provider visit, prescription, compounded medication, and USPS shipping into a single flat monthly rate. Neither program charges setup fees, annual memberships, or consultation bills beyond the medication subscription.

The operational difference lies in dosing and titration: branded medications ship in fixed-dose pens (Ozempic 0.25/0.5 mg, 1 mg, or 2 mg prefilled devices; Mounjaro 2.5 mg through 15 mg single-dose pens; Wegovy 0.25 mg through 2.4 mg dose escalation packs). Dose changes typically require a new pen shipment. Compounded formulations from PlexusDx arrive as multi-dose vials, allowing clinician-directed titration within a single vial and reducing waste when adjusting dosage. PlexusDx maintains the same $189 or $289 flat rate at every dose of semaglutide or tirzepatide injection, whereas branded pen formats implicitly constrain titration to the manufacturer's escalation schedule.

Cancellation and lock-in

Levity permits cancellation at any time with no early-termination penalty (confirmed September 4, 2026 via public site footer and intake flow). PlexusDx month-to-month subscriptions likewise carry no contract commitment; patients may pause or cancel before the next billing date without fee. Both programs therefore offer equivalent subscription flexibility, and neither imposes a multi-month prepayment obligation.

Insurance and manufacturer coupons

Levity dispenses branded drugs that may be eligible for insurance coverage if prescribed for an FDA-approved indication (Ozempic and Mounjaro for type 2 diabetes, Wegovy for chronic weight management). Many commercial and Medicare Part D plans exclude or heavily restrict GLP-1s for weight loss, and Levity's telehealth model does not guarantee insurance billing. The published self-pay rates—$1,199 to $1,599 per four weeks—apply when insurance does not cover the medication or when the patient opts for out-of-pocket payment.

Manufacturer savings cards (Novo Nordisk or Eli Lilly programs) occasionally reduce branded copays to as low as $25 per month for commercially insured patients, but these coupons exclude Medicare beneficiaries, often require prior authorization, carry eligibility restrictions, and may be subject to annual benefit caps or sudden program changes. Patients considering Levity should confirm current coupon availability and their own insurance formulary status before assuming a low net cost. PlexusDx compounded medications are not eligible for brand manufacturer coupons and are typically not covered by insurance; the $189 or $289 stated rate is the all-in cash price.

Medication availability and shortage considerations

Branded semaglutide and tirzepatide periodically appear on the FDA drug shortage list, constraining supply at both retail pharmacies and telehealth dispensaries. Levity's access to Ozempic, Mounjaro, and Wegovy depends on Novo Nordisk and Eli Lilly manufacturing throughput and allocation decisions. When shortage conditions ease, Levity resumes or expands branded fulfillment; when shortages tighten, the intake may close or delay shipments.

Compounded semaglutide and tirzepatide from 503A pharmacies remain legally available during periods of branded shortage under FDA and state pharmacy board guidance. PlexusDx sources active pharmaceutical ingredient from FDA-registered suppliers and maintains relationships with multiple 503A facilities to reduce single-point-of-failure risk. Shortage dynamics favor compounded supply continuity in constrained markets, though compounded options disappear or face new restrictions if FDA declares the branded shortage resolved.

Choose Levity if…

• You require or strongly prefer FDA-approved branded formulations and are willing to pay five to nine times the compounded alternative price for that regulatory assurance.
• Your insurance plan covers Ozempic, Mounjaro, or Wegovy with a manageable copay and Levity can bill your plan (confirm at intake; the $1,199–$1,599 rates apply when insurance does not pay).
• You hold an active manufacturer savings card that reduces your net branded cost below the compounded cash rate.
• You value the brand-manufacturer pen device format and prefer not to handle multi-dose vials and syringes.

Choose PlexusDx if…

• Lowering your annual medication spend by $13,000 or more is a priority, and you accept compounded semaglutide or tirzepatide prepared by licensed 503A pharmacies.
• You want a single flat rate that never changes with dose escalation—$189 for semaglutide injection or $289 for tirzepatide injection, month after month.
• You prefer flexible dose titration within a multi-dose vial rather than waiting for a new prefilled pen when adjusting dosage.
• Your insurance excludes GLP-1s for weight management or you lack insurance altogether, making transparent cash pricing decision-critical.

Methodology and freshness

Levity pricing, billing cadence, inclusions, and promotional terms were verified by completing the public intake at https://www.joinlevity.com/ on September 4, 2026 13:49:55 UTC. No payment was submitted; figures reflect the checkout preview screen and published website rates. PlexusDx pricing was captured July 17–23, 2026 from live product pages at https://plexusdx.com/ and reconfirmed against the published rate schedule. Trustpilot profiles for both Levity (https://www.trustpilot.com/review/joinlevity.com) and PlexusDx (https://www.trustpilot.com/review/plexusdx.com, 4.3-star rating with 79% five-star reviews, captured September 9, 2026) exist; no Levity rating or volume was recorded in this research pass.

52-week totals and effective monthly costs are our calculations, derived by summing the first-supply charge plus twelve subsequent four-week refills for Levity (13 billing cycles over 52 weeks), then dividing by 12 to produce a monthly-equivalent figure. PlexusDx 12-month totals multiply the stated monthly rate by 12. Savings percentages and annual cost differences are likewise our calculations. All figures are U.S. dollars and exclude taxes where applicable.

Frequently Asked Questions

Does Levity charge a membership fee on top of medication costs?

No. Levity's published per-cycle price includes medication, clinician consultation, care access, and shipping with no separate membership fee. The $1,199 to $1,599 four-week rate is all-inclusive, verified September 4, 2026.

Can I use a manufacturer coupon with Levity Ozempic or Wegovy?

Manufacturer savings cards from Novo Nordisk or Eli Lilly may reduce branded copays if your insurance covers the medication and you meet coupon eligibility rules (commercial insurance, prior authorization approval, no Medicare). Confirm current coupon availability and your plan's formulary before assuming low net cost; the $1,199–$1,599 self-pay rates apply when insurance or coupons do not pay.

Why is compounded semaglutide so much cheaper than Ozempic?

Compounded formulations bypass brand-manufacturer supply chains and do not carry the development-cost premium embedded in FDA-approved branded pricing. The active pharmaceutical ingredient is identical, but compounded drugs are prepared by 503A pharmacies under state pharmacy board oversight and are not FDA-approved. The $13,269 annual difference between Levity Ozempic and PlexusDx compounded semaglutide reflects these regulatory and supply-chain distinctions.

How often does Levity bill, and how many payments will I make in a year?

Levity bills approximately every four weeks (28 days), resulting in 13 billing cycles over a 52-week year rather than 12 calendar months. A full year of Ozempic therefore costs the first-month rate of $1,149 plus twelve refills at $1,199 each, totaling $15,537—not $1,199 multiplied by 12.

Does PlexusDx match Levity's branded medication offering?

No. PlexusDx dispenses compounded semaglutide and tirzepatide prepared by licensed 503A compounding pharmacies, not FDA-approved branded Ozempic, Mounjaro, or Wegovy. The active pharmaceutical ingredient is the same, but the finished formulation, regulatory status, device format, and price are different. Patients requiring or preferring branded drugs should consider Levity or a retail pharmacy; patients prioritizing cost savings may choose compounded alternatives.

Sources

• PlexusDx product pages and rate schedule, captured July 17–23, 2026, https://plexusdx.com/
• Levity intake flow and checkout preview, captured September 4, 2026 13:49:55 UTC, https://www.joinlevity.com/
• Levity website published pricing grid, captured September 4, 2026 13:49:55 UTC, https://www.joinlevity.com/
• Trustpilot profile, Levity, accessed September 4, 2026, https://www.trustpilot.com/review/joinlevity.com
• Trustpilot profile, PlexusDx, 4.3-star rating, 79% five-star reviews, accessed September 9, 2026, https://www.trustpilot.com/review/plexusdx.com

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.